"Plus Therapeutics (PSTV) reported a second-quarter loss and missed revenue estimates, although it has turned profitable with the upcoming launch of a new cancer detection tool. The company also received an extension to meet Nasdaq listing requirements, but overall sentiment remains cautious due to its financial performance and market challenges."